This is crucial in countries with poor or nonexistent Drug Regulatory Authorities and is normally consistent with our Corporate Responsibility. This plan has been praised in particular by patient curiosity organisations from resource-limited countries suffering from low-quality products. Being aware of our responsibility and actively striving for the idea of a pool Boehringer Ingelheim welcome the UNITAIDs initiative. We’ve been in constructive discussions with the promoters of the pool idea for quite a while and we will carefully observe future advancements. For now we are certain that our strategy as promoted for example also by academic organizations is the better option.With the completion of two acquisitions in the quarter, Alexion’s non-GAAP operating outcomes will now also exclude amortization of obtained intangible resources and costs connected with acquisitions. The following summary desk is provided for traders’ convenience: First Quarter Non-GAAP Financial Results: THE BUSINESS reported non-GAAP net gain of $56.3 million, or $0.59 per share, for the first quarter of 2011, compared to non-GAAP net income of $34.6 million, or $0.37 per share, in the initial quarter of 2010. Alexion’s non-GAAP operating expenses for Q1 2011 were $85.9 million, in comparison to $65.2 million for Q1 2010.